Ad is loading...
HYPR
Price
$0.98
Change
+$0.08 (+8.89%)
Updated
Nov 21 closing price
117 days until earnings call
ICAD
Price
$1.54
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
96 days until earnings call
Ad is loading...

HYPR vs ICAD

Header iconHYPR vs ICAD Comparison
Open Charts HYPR vs ICADBanner chart's image
Hyperfine
Price$0.98
Change+$0.08 (+8.89%)
Volume$220.35K
CapitalizationN/A
iCAD
Price$1.54
Change-$0.00 (-0.00%)
Volume$223.49K
CapitalizationN/A
HYPR vs ICAD Comparison Chart
Loading...
HYPR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ICAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
HYPR vs. ICAD commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HYPR is a StrongBuy and ICAD is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (HYPR: $0.98 vs. ICAD: $1.54)
Brand notoriety: HYPR and ICAD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: HYPR: 244% vs. ICAD: 109%
Market capitalization -- HYPR: $70.76M vs. ICAD: $42.43M
HYPR [@Medical Specialties] is valued at $70.76M. ICAD’s [@Medical Specialties] market capitalization is $42.43M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HYPR’s FA Score shows that 1 FA rating(s) are green whileICAD’s FA Score has 0 green FA rating(s).

  • HYPR’s FA Score: 1 green, 4 red.
  • ICAD’s FA Score: 0 green, 5 red.
According to our system of comparison, both HYPR and ICAD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HYPR’s TA Score shows that 6 TA indicator(s) are bullish while ICAD’s TA Score has 3 bullish TA indicator(s).

  • HYPR’s TA Score: 6 bullish, 3 bearish.
  • ICAD’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, HYPR is a better buy in the short-term than ICAD.

Price Growth

HYPR (@Medical Specialties) experienced а +9.74% price change this week, while ICAD (@Medical Specialties) price change was -13.73% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.47%. For the same industry, the average monthly price growth was -1.10%, and the average quarterly price growth was -2.69%.

Reported Earning Dates

HYPR is expected to report earnings on Mar 19, 2025.

ICAD is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Medical Specialties (+0.47% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HYPR($70.8M) has a higher market cap than ICAD($42.4M). HYPR (-12.893) and ICAD (-12.994) have similar YTD gains . ICAD has higher annual earnings (EBITDA): -12.18M vs. HYPR (-47.06M). HYPR has more cash in the bank: 75.2M vs. ICAD (19M). HYPR has less debt than ICAD: HYPR (185K) vs ICAD (514K). ICAD has higher revenues than HYPR: ICAD (25.4M) vs HYPR (11M).
HYPRICADHYPR / ICAD
Capitalization70.8M42.4M167%
EBITDA-47.06M-12.18M387%
Gain YTD-12.893-12.99499%
P/E RatioN/AN/A-
Revenue11M25.4M43%
Total Cash75.2M19M396%
Total Debt185K514K36%
FUNDAMENTALS RATINGS
ICAD: Fundamental Ratings
ICAD
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
91
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
HYPRICAD
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
63%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
61%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 15 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
HYPR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ICAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NKE75.101.74
+2.37%
Nike
ENVA102.022.15
+2.15%
Enova International
ALRS21.890.39
+1.81%
Alerus Financial Corp
UI345.724.73
+1.39%
Ubiquiti
USGO10.12-0.33
-3.16%
US GoldMining

HYPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, HYPR has been loosely correlated with ALGN. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HYPR jumps, then ALGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HYPR
1D Price
Change %
HYPR100%
+8.40%
ALGN - HYPR
33%
Loosely correlated
+1.94%
SGHT - HYPR
33%
Loosely correlated
+0.80%
ICAD - HYPR
29%
Poorly correlated
-0.32%
RSLS - HYPR
29%
Poorly correlated
+10.71%
TMCI - HYPR
28%
Poorly correlated
-0.50%
More

ICAD and

Correlation & Price change

A.I.dvisor tells us that ICAD and HAE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICAD and HAE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICAD
1D Price
Change %
ICAD100%
-0.32%
HAE - ICAD
32%
Poorly correlated
+0.60%
NARI - ICAD
29%
Poorly correlated
+1.53%
HYPR - ICAD
29%
Poorly correlated
+8.40%
MDXH - ICAD
29%
Poorly correlated
+5.56%
CVRX - ICAD
27%
Poorly correlated
+9.25%
More